| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8317094 | Clinical Biochemistry | 2018 | 4 Pages |
Abstract
- Daratumumab and other mAb therapeutics can appear as M-proteins on SPEP and IFE.
- mAb interference can be erroneously diagnosed as disease progression, class switching, development of a new clone, or MRD.
- Strategies to identify interference include characterizing mAb elution sites and active communication with clinicians.
- Specialized assays such as DIRA may help resolve cases of co-migrating disease M-protein and mAb.
- New protein MS assays may also be developed to unambiguously identify mAbs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Odise Cenaj, Jayme L. Dahlin, Dulce M. Buencamino, Jacob P. Laubach, Petr Jarolim,